AllCourtTENNIS
Explorer
This SELECT trial analysis involved more than 17,000 individuals who had overweight/obesity along with established cardiovascular disease, but did not have diabetes. hsCRP testing served as the method for assessing systemic inflammation. A drop in Major Adverse Cardiovascular Events (MACE) risk was observed starting at 4-8 weeks after treatment began.
"Higher hsCRP levels (≥10 mg/L) were associated with a 2- to 4-fold higher risk of major adverse cardiovascular events, cardiovascular death, and all-cause death versus levels <2 mg/L.
Semaglutide reduced hsCRP levels and cardiovascular risk across all baseline hsCRP levels, with effects preceding major weight loss, in those without weight loss, and independently of other measures (eg, cholesterol levels, statin use, atherosclerotic cardiovascular disease entry criteria)."
Study link
"Higher hsCRP levels (≥10 mg/L) were associated with a 2- to 4-fold higher risk of major adverse cardiovascular events, cardiovascular death, and all-cause death versus levels <2 mg/L.
Semaglutide reduced hsCRP levels and cardiovascular risk across all baseline hsCRP levels, with effects preceding major weight loss, in those without weight loss, and independently of other measures (eg, cholesterol levels, statin use, atherosclerotic cardiovascular disease entry criteria)."
Study link
